High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy

Keisuke Shigeta, Takeo Kosaka, Shigehisa Kitano, Yota Yasumizu, Yasumasa Miyazaki, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Akira Miyajima, Hitoshi Tanoguchi, Shintaro Hasegawa, Mototsugu Oya

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAnnals of Surgical Oncology
DOIs
Publication statusAccepted/In press - 2016 Jun 30

Fingerprint

docetaxel
Castration
Monocytes
Prostatic Neoplasms
Prostate-Specific Antigen
Drug Therapy
Disease-Free Survival
Tumor Microenvironment
Survival
Medical Records
Regression Analysis
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy. / Shigeta, Keisuke; Kosaka, Takeo; Kitano, Shigehisa; Yasumizu, Yota; Miyazaki, Yasumasa; Mizuno, Ryuichi; Shinojima, Toshiaki; Kikuchi, Eiji; Miyajima, Akira; Tanoguchi, Hitoshi; Hasegawa, Shintaro; Oya, Mototsugu.

In: Annals of Surgical Oncology, 30.06.2016, p. 1-8.

Research output: Contribution to journalArticle

Shigeta, Keisuke ; Kosaka, Takeo ; Kitano, Shigehisa ; Yasumizu, Yota ; Miyazaki, Yasumasa ; Mizuno, Ryuichi ; Shinojima, Toshiaki ; Kikuchi, Eiji ; Miyajima, Akira ; Tanoguchi, Hitoshi ; Hasegawa, Shintaro ; Oya, Mototsugu. / High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy. In: Annals of Surgical Oncology. 2016 ; pp. 1-8.
@article{3f4f87329cd44952babfc8f415f03791,
title = "High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy",
abstract = "Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb",
author = "Keisuke Shigeta and Takeo Kosaka and Shigehisa Kitano and Yota Yasumizu and Yasumasa Miyazaki and Ryuichi Mizuno and Toshiaki Shinojima and Eiji Kikuchi and Akira Miyajima and Hitoshi Tanoguchi and Shintaro Hasegawa and Mototsugu Oya",
year = "2016",
month = "6",
day = "30",
doi = "10.1245/s10434-016-5354-5",
language = "English",
pages = "1--8",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy

AU - Shigeta, Keisuke

AU - Kosaka, Takeo

AU - Kitano, Shigehisa

AU - Yasumizu, Yota

AU - Miyazaki, Yasumasa

AU - Mizuno, Ryuichi

AU - Shinojima, Toshiaki

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Tanoguchi, Hitoshi

AU - Hasegawa, Shintaro

AU - Oya, Mototsugu

PY - 2016/6/30

Y1 - 2016/6/30

N2 - Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb

AB - Background: The association of peripheral monocyte count and prostate cancer progression is not well characterized. Objective: Our aim was to investigate the prognostic value of absolute monocyte count (AMC), which is thought to modulate immune response in the tumor microenvironment, in castration-resistant prostate cancer (CRPC) patients treated with docetaxel chemotherapy. Methods: We retrospectively reviewed the medical records of 214 CRPC patients who received docetaxel therapy and were used as the training and validation set. Docetaxel at a dose of 75 mg/m2 was administered every 3 or 4 weeks. Clinicopathological factors and laboratory data were collected to assess the prognostic factors for overall survival (OS) and progression-free survival (PFS). Results: In the training set, the median age was 73.0 years, and the median prostate-specific antigen (PSA) value was 31.7 ng/ml at initial treatment. The median OS and PFS were 23.0 months (range 1.20–84.0) and 11.2 months (range 3.6–78.0), respectively. According to multivariable Cox regression analysis, AMC ≥400/uL, PSA level ≥20 ng/ml, and Hb

UR - http://www.scopus.com/inward/record.url?scp=84976500598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976500598&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5354-5

DO - 10.1245/s10434-016-5354-5

M3 - Article

C2 - 27364499

AN - SCOPUS:84976500598

SP - 1

EP - 8

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -